概述
-
货号
DVV02804
-
描述
Felvizumab [HuRSV19VHFNS/VK, RSHZ19, RSV monoclonal antibody, SB 209763] is a humanised monoclonal antibody (IgG1) prepared by the humanization of an F protein-specific murine MAb. In in vitro studies, palivizumab, another humanized Mab specific for the F protein of RSV, was 4 to 5-fold more potent than felvizumab in neutralising RSV (Scott, 1999). RSHZ19 (Felvizumab) RSV This antibody was
-
表达系统
Mammalian Cells -
种属反应性
HRSV-A -
宿主
Humanized -
同种型
IgG1, kappa -
克隆类型
Monoclonal -
靶标
F, Fusion glycoprotein F0, Fusion glycoprotein F2, p27, Intervening segment, Pep27, Peptide 27, Fusion glycoprotein F1 -
浓度
1 mg/ml -
内毒素水平
Please contact with the lab for this information. -
纯度
>95% as determined by SDS-PAGE. -
纯化方式
Protein A/G purified from cell culture supernatant. -
Accession号
P03420 -
克隆号
Felvizumab
-
应用
Research Grade Biosimilar -
状态
Liquid -
保存溶液
0.01M PBS, pH 7.4. -
稳定性和存储
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term. -
别名
SB 209763, HuRSV19VHFNS/VK, RSHZ19 monoclonal antibody, SB 209763, CAS: 167747-20-8
图片
参考文献
评价
